Adsorption of rhG-CSF to Various Intravenous Filters (2).

rhG-CSF resistant neutropenia in SLE.

Long-term safety of filgrastim (rhG-CSF) administration

This journal recently included an article by Bennett et al (2006) reporting five cases of haematological malignancy occurring in normal individuals following exposure to haematopoietic growth factors. Three cases described lymphoid malignancies (non-Hodgkin lymphoma and chronic lymphocytic leukaemia) occurring months to years after receipt of an investigational agent (pegylated, recombinant meg...

Response to cyclosporin A and rhG-CSF in a case of aplastic anemia.

A 23-year-old male patient developed aplastic anemia and was treated with cyclosporin A and rhG-CSF. Bone marrow biopsy showed an improvement in cellularity with a recovery of all hematopoietic precursors after nine weeks of therapy. WBC increased after two weeks of treatment, mostly due to an increase in the absolute granulocyte cell count. Hb, RBC, Plts and reticulocytes showed an increase si...

Protein adsorption to hydrocephalus shunt catheters: CSF protein adsorption.

OBJECTIVE To assess the quantity and nature of the proteins that adsorb to hydrocephalus shunt catheters after implantation, and to determine whether sufficient could accumulate to obstruct the catheter. DESIGN Elution of proteins from 102 explanted shunt catheters, with protein assay and electrophoresis of the eluate, and scanning electron microscopy (SEM) of the catheters. RESULTS The amo...

Comparison of two regimens of RhG-CSF in neutropenic neonatal septicemia: a randomized clinical trial.

Considering the 50% mortality rate of neonatal septicemia associated with neutropenia and increasing resistance to antibiotics, simultaneous antibiotic therapy strategies are becoming more important. However, few studies have been performed to evaluate effectiveness of RhG-CSF in the treatment of neutropenia in neonates. This randomized clinical trial was performed on 40 neutropenic neonates wi...